Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial
Valérie Boige(Inserm), Pierre Laurent‐Puig(Inserm), Marc Vincent(Délégation Paris 5), Isabelle Miran(Inserm), Sophie Gourgou(Université de Montpellier), Ludovic Bigot(Inserm), Caroline Mollévi(Inserm), Béata Juzyna(UniCancer Group), Jean‐Pierre Gerard(Centre Antoine Lacassagne), Jean‐François Seitz(Aix-Marseille Université), D. Azria(Inserm)
Cited by 11
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k